RE: Now 3 weeks since "in the coming days"21 May 2021 15:51
Ndn - What utter rubbish! No way would they have got this passage in the RNS of 10 May past the Nomad if it wasn't fact.
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the Declaration of Conformity for CE mark of its AffiDX® SARS-CoV-2 antigen rapid test for professional use has been submitted to the Medicines and Healthcare products Regulatory Agency ("MHRA") through the Group's partner Mologic Limited.